FUS/TLS Inhibitors

Common FUS/TLS Inhibitors include, but are not limited to Rapamycin CAS 53123-88-9, Mitoxantrone CAS 65271-80-9, Doxorubicin CAS 23214-92-8, Fluorouracil CAS 51-21-8 and Hydroxyurea CAS 127-07-1.

FUS/TLS (Fused in Sarcoma/Translocated in Liposarcoma) is a multifunctional DNA/RNA binding protein that plays integral roles in various cellular processes, including DNA repair, RNA splicing, RNA transport, and the regulation of gene expression. It is primarily located in the nucleus but can shuttle between the nucleus and the cytoplasm. Given its diverse roles and interactions with both DNA and RNA, FUS/TLS is considered crucial for maintaining cellular homeostasis and genomic integrity. Mutations or mislocalizations of FUS/TLS have been linked to certain neurodegenerative diseases, highlighting its importance in neural cellular functions.

FUS/TLS Inhibitors are a category of chemical compounds designed to dampen or suppress the activity of the FUS/TLS protein. These inhibitors can function through various mechanisms. Some might directly bind to FUS/TLS, altering its structure and preventing it from interacting with its natural DNA or RNA targets. Others might impede its shuttling between the nucleus and cytoplasm, thereby disrupting its regular cellular functions. Additionally, certain inhibitors might target pathways or enzymes responsible for the post-translational modifications of FUS/TLS, which are crucial for its activity and localization. By inhibiting the functionality of FUS/TLS, these chemical compounds can help elucidate the protein's roles in diverse cellular processes and its significance in maintaining cellular and genomic stability. These inhibitors provide a valuable toolset for researchers aiming to delve deeper into the complex biology of FUS/TLS and its myriad interactions within the cell.